{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:10:14Z","timestamp":1785431414182,"version":"3.56.0"},"posted":{"date-parts":[[2026,7,7]]},"group-title":"Cancer Biology","reference-count":55,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["P30CA015704"],"award-info":[{"award-number":["P30CA015704"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["P30CA014051"],"award-info":[{"award-number":["P30CA014051"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["F30CA268633"],"award-info":[{"award-number":["F30CA268633"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R35CA242379"],"award-info":[{"award-number":["R35CA242379"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA259253"],"award-info":[{"award-number":["R01CA259253"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32GM007270"],"award-info":[{"award-number":["T32GM007270"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["R35GM147118"],"award-info":[{"award-number":["R35GM147118"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32GM007753"],"award-info":[{"award-number":["T32GM007753"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32GM007287"],"award-info":[{"award-number":["T32GM007287"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science Foundation","award":["DGE-2140004"],"award-info":[{"award-number":["DGE-2140004"]}]},{"name":"Levinson Emerging Scholars Award"},{"DOI":"10.13039\/100015991","name":"Ludwig Center at MIT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015991","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MIT Center for Precision Cancer Medicine"},{"name":"Intramural Research Program of the National Institutes of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Dissecting how metabolite availability impacts drug sensitivity is critical for understanding therapy resistance. While proteasome inhibitors like the boronic acid proteasome inhibitor bortezomib are cornerstones of therapy for multiple myeloma, the clinical utility of these drugs is often limited by development of resistance, the metabolic drivers of which remain poorly understood. In this study, we find that \u03b1-ketoacids, including pyruvate, increase sensitivity to boronic acid proteasome inhibitors independent of their conventional roles in metabolism. Instead, \u03b1-ketoacids directly react with intracellular cysteine to form thiazolidines, sequestering cysteine away from forming conjugates with boronic acid proteasome inhibitors and detoxifying these drugs. Preventing cysteine-mediated detoxification through \u03b1-ketoacid supplementation increases the efficacy of boronic acid proteasome inhibitors, leading to greater proteasome inhibition and cytotoxicity that is reversed by cysteine supplementation. These findings suggest that modulating available cysteine through \u03b1-ketoacid interactions can impact effective levels of some drugs in cells, and represent a potential strategy to overcome resistance and maximize the efficacy of boronic acid proteasome inhibitors.<\/jats:p>","DOI":"10.64898\/2026.07.06.736827","type":"posted-content","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:29:22Z","timestamp":1783430962000},"source":"Crossref","is-referenced-by-count":0,"title":["Cysteine-mediated bortezomib resistance is governed by \u03b1-ketoacid availability"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-6255","authenticated-orcid":false,"given":"Jennifer A.","family":"Brain","sequence":"first","affiliation":[{"name":"Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0036-1071","authenticated-orcid":false,"given":"Sarah M.","family":"Chang","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"name":"Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0124-101X","authenticated-orcid":false,"given":"Maximilian","family":"Kobiesa","sequence":"additional","affiliation":[{"name":"Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah G.","family":"Rector","sequence":"additional","affiliation":[{"name":"Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-9521","authenticated-orcid":false,"given":"Michele","family":"Ceribelli","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sky H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqi","family":"Li","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"name":"Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4992-2623","authenticated-orcid":false,"given":"Brian T.","family":"Do","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"name":"Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli J.","family":"Che","sequence":"additional","affiliation":[{"name":"Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holland","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3998-0122","authenticated-orcid":false,"given":"Samuel","family":"Block","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"name":"Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Chang","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"name":"Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4770-9021","authenticated-orcid":false,"given":"Gillian E.","family":"Oaks","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"name":"Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-4192","authenticated-orcid":false,"given":"Matthew G.","family":"Vander Heiden","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"name":"Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA"},{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-8222","authenticated-orcid":false,"given":"Lucas B.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026070922152412000_2026.07.06.736827v1.1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.chembiol.2023.08.007","article-title":"Screening in serum-derived medium reveals differential response to compounds targeting metabolism","volume":"30","year":"2023","journal-title":"Cell Chem. Biol"},{"key":"2026070922152412000_2026.07.06.736827v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.03.023"},{"key":"2026070922152412000_2026.07.06.736827v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.09.006"},{"key":"2026070922152412000_2026.07.06.736827v1.4","doi-asserted-by":"crossref","unstructured":"Muir, A. et al. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. eLife 6, (2017).","DOI":"10.7554\/eLife.27713"},{"key":"2026070922152412000_2026.07.06.736827v1.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar5986"},{"key":"2026070922152412000_2026.07.06.736827v1.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw9872"},{"key":"2026070922152412000_2026.07.06.736827v1.7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4267"},{"key":"2026070922152412000_2026.07.06.736827v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600786"},{"key":"2026070922152412000_2026.07.06.736827v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.016"},{"key":"2026070922152412000_2026.07.06.736827v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.017"},{"key":"2026070922152412000_2026.07.06.736827v1.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016627108"},{"key":"2026070922152412000_2026.07.06.736827v1.12","doi-asserted-by":"crossref","unstructured":"Hart, M. L. et al. Mitochondrial redox adaptations enable alternative aspartate synthesis in SDH-deficient cells. eLife 12, (2023).","DOI":"10.7554\/eLife.78654"},{"key":"2026070922152412000_2026.07.06.736827v1.13","doi-asserted-by":"crossref","unstructured":"Rattigan, K. M. et al. Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells. Nat. Commun. 14, (2023).","DOI":"10.1038\/s41467-023-40222-z"},{"key":"2026070922152412000_2026.07.06.736827v1.14","doi-asserted-by":"crossref","unstructured":"Singleton, D. C. et al. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. BMC Cancer 20, (2020).","DOI":"10.1186\/s12885-020-06885-3"},{"key":"2026070922152412000_2026.07.06.736827v1.15","doi-asserted-by":"crossref","first-page":"218245","DOI":"10.1016\/j.canlet.2026.218245","article-title":"The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism","volume":"640","year":"2026","journal-title":"Cancer Lett"},{"key":"2026070922152412000_2026.07.06.736827v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90396-4"},{"key":"2026070922152412000_2026.07.06.736827v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-024-00778-0"},{"key":"2026070922152412000_2026.07.06.736827v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/386463a0"},{"key":"2026070922152412000_2026.07.06.736827v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80341-X"},{"key":"2026070922152412000_2026.07.06.736827v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2012.01.003"},{"key":"2026070922152412000_2026.07.06.736827v1.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"2026070922152412000_2026.07.06.736827v1.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"2026070922152412000_2026.07.06.736827v1.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"2026070922152412000_2026.07.06.736827v1.24","first-page":"887","article-title":"Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma","volume":"35","year":"2020","journal-title":"Leukemia"},{"key":"2026070922152412000_2026.07.06.736827v1.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104950"},{"key":"2026070922152412000_2026.07.06.736827v1.26","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070188"},{"key":"2026070922152412000_2026.07.06.736827v1.27","doi-asserted-by":"publisher","DOI":"10.1021\/jm300434z"},{"key":"2026070922152412000_2026.07.06.736827v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.12.001"},{"key":"2026070922152412000_2026.07.06.736827v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.05.006"},{"key":"2026070922152412000_2026.07.06.736827v1.30","doi-asserted-by":"crossref","unstructured":"Sharma, A. et al. Therapeutic implications of mitochondrial stress\u2013induced proteasome inhibitor resistance in multiple myeloma. Sci. Adv. 8, (2022).","DOI":"10.1126\/sciadv.abq5575"},{"key":"2026070922152412000_2026.07.06.736827v1.31","doi-asserted-by":"crossref","unstructured":"Zaal, E. A. et al. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 5, (2017).","DOI":"10.1186\/s40170-017-0169-9"},{"key":"2026070922152412000_2026.07.06.736827v1.32","doi-asserted-by":"publisher","DOI":"10.1007\/s13353-025-01022-x"},{"key":"2026070922152412000_2026.07.06.736827v1.33","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1038\/bcj.2016.56","article-title":"Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells","volume":"6","year":"2016","journal-title":"Blood Cancer J"},{"key":"2026070922152412000_2026.07.06.736827v1.34","doi-asserted-by":"crossref","unstructured":"Sullivan, M. R. et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife 8, (2019).","DOI":"10.7554\/eLife.44235"},{"key":"2026070922152412000_2026.07.06.736827v1.35","unstructured":"Lin, G. L. et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci. Transl. Med. 11, (2019)."},{"key":"2026070922152412000_2026.07.06.736827v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/75406"},{"key":"2026070922152412000_2026.07.06.736827v1.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0605"},{"key":"2026070922152412000_2026.07.06.736827v1.38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.537175"},{"key":"2026070922152412000_2026.07.06.736827v1.39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s42255-022-00588-8","article-title":"Cancer cells depend on environmental lipids for proliferation when electron acceptors are limited","volume":"4","year":"2022","journal-title":"Nat. Metab"},{"key":"2026070922152412000_2026.07.06.736827v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.08.003"},{"key":"2026070922152412000_2026.07.06.736827v1.41","doi-asserted-by":"publisher","DOI":"10.64898\/2026.03.18.712640"},{"key":"2026070922152412000_2026.07.06.736827v1.42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s42255-026-01499-8","article-title":"Excess cysteine drives conjugate formation and impairs proliferation of NRF2-activated cancer cells","volume":"8","year":"2026","journal-title":"Nat. Metab"},{"key":"2026070922152412000_2026.07.06.736827v1.43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0021-9258(20)65226-7","article-title":"COMPOUNDS OF THIOL ACIDS WITH ALDEHYDES","volume":"114","year":"1936","journal-title":"J. Biol. Chem"},{"key":"2026070922152412000_2026.07.06.736827v1.44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0021-9258(18)74286-5","article-title":"REACTIONS OF SEMIMERCAPTALS WITH AMINO COMPOUNDS","volume":"121","year":"1937","journal-title":"J. Biol. Chem"},{"key":"2026070922152412000_2026.07.06.736827v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2005.11.019"},{"key":"2026070922152412000_2026.07.06.736827v1.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-171389"},{"key":"2026070922152412000_2026.07.06.736827v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.83"},{"key":"2026070922152412000_2026.07.06.736827v1.48","doi-asserted-by":"publisher","DOI":"10.1021\/tx050313d"},{"key":"2026070922152412000_2026.07.06.736827v1.49","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002956"},{"key":"2026070922152412000_2026.07.06.736827v1.50","first-page":"289","article-title":"Transport of cystine and cysteine in mammalian cells","volume":"779","year":"1984","journal-title":"Biochim. Biophys. Acta BBA - Rev. Biomembr"},{"key":"2026070922152412000_2026.07.06.736827v1.51","doi-asserted-by":"publisher","DOI":"10.1038\/nature10189"},{"key":"2026070922152412000_2026.07.06.736827v1.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.10.009"},{"key":"2026070922152412000_2026.07.06.736827v1.53","first-page":"412","article-title":"Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis","volume":"29","year":"2023","journal-title":"Apoptosis"},{"key":"2026070922152412000_2026.07.06.736827v1.54","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.3390\/molecules25184323","article-title":"Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications","volume":"25","year":"2020","journal-title":"Molecules"},{"key":"2026070922152412000_2026.07.06.736827v1.55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311846111"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.07.06.736827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:15:38Z","timestamp":1783660538000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.07.06.736827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":55,"URL":"https:\/\/doi.org\/10.64898\/2026.07.06.736827","relation":{},"subject":[],"published":{"date-parts":[[2026,7,7]]},"subtype":"preprint"}}